Jonathan Barratt

Prof. Jonathan Barratt

Renal Research Group, University of Leicester, Leicester LE1 9HN, UK
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Kidney International
Verified
Journal Article
Open access
BRBrad H. Rovin
Brad H. Rovin
SASharon G. Adler
Sharon G. Adler
JBJonathan Barratt
Jonathan Barratt
FBFrank Bridoux
Frank Bridoux
KBKelly A. Burdge
Kelly A. Burdge
JFJürgen Floege
Jürgen Floege

1 May 2017 in Kidney International
Verified
Journal Article
Closed access
HTHERNAN TRIMARCHI
HERNAN TRIMARCHI
JBJonathan Barratt
Jonathan Barratt
DCDaniel C. Cattran
Daniel C. Cattran
HCH. Terence Cook
H. Terence Cook
RCRosanna Coppo
Rosanna Coppo
CZCaihong Zeng
Caihong Zeng

1 September 2009 in Kidney International
Verified
Journal Article
Closed access
ASA Working Group of the International IgA Nephropathy Network and the Renal Pathology Society
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society
DCDaniel C. Cattran
Daniel C. Cattran
RCRosanna Coppo
Rosanna Coppo
HCH. Terence Cook
H. Terence Cook
JFJohn Feehally
John Feehally
HZHong Zhang
Hong Zhang

1 September 2009 in Kidney International
Verified
Journal Article
Closed access
ASA Working Group of the International IgA Nephropathy Network and the Renal Pathology Society
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society
IRIan S.D. Roberts
Ian S.D. Roberts
HCH. Terence Cook
H. Terence Cook
STStéphan Troyanov
Stéphan Troyanov
CACharles E. Alpers
Charles E. Alpers
HZHong Zhang
Hong Zhang

1 October 2021 in Kidney International
Verified
Journal Article
Open access
BRBrad H. Rovin
Brad H. Rovin
SASharon G. Adler
Sharon G. Adler
JBJonathan Barratt
Jonathan Barratt
FBFrank Bridoux
Frank Bridoux
KBKelly A. Burdge
Kelly A. Burdge
JFJürgen Floege
Jürgen Floege
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (GN), both adults and children. The scope includes various glomerular diseases, including IgA nephropathy and IgA vasculitis, membranous nephropathy, nephrotic syndrome, minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), infection-related GN, antineutrophil cytoplasmic antibody (ANCA) vasculitis, lupus nephritis, and anti-glomerular basement membrane antibody GN. In addition, this guideline will be the first to address the subtype of complement-mediated diseases. Each chapter follows the same format providing guidance related to diagnosis, prognosis, treatment, and special situations. The goal of the guideline is to generate a useful resource for clinicians and patients by providing actionable recommendations based on evidence syntheses, with useful infographics incorporating views from experts in the field. Another aim is to propose research recommendations for areas where there are gaps in knowledge. The guideline targets a broad global audience of clinicians treating GN while being mindful of implications for policy and cost. Development of this guideline update followed an explicit process whereby treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed, with areas of future research also presented.

12 October 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
YIFU LIYIFU LI
YIFU LI
FSFrancesco Scolari
Francesco Scolari
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
MCMurim Choi
Murim Choi
AGAli G Gharavi
Ali G Gharavi
Ali Gharavi and colleagues report a genome-wide association analysis of IgA nephropathy in over 20,000 individuals of European and East Asian ancestry. They identify genome-wide significant signals at three new loci near VAV3, CARD9 and ITGAM-ITGAX and correlations between genetic risk and pathogen diversity. We performed a genome-wide association study (GWAS) of IgA nephropathy (IgAN), the most common form of glomerulonephritis, with discovery and follow-up in 20,612 individuals of European and East Asian ancestry. We identified six new genome-wide significant associations, four in ITGAM-ITGAX, VAV3 and CARD9 and two new independent signals at HLA-DQB1 and DEFA. We replicated the nine previously reported signals, including known SNPs in the HLA-DQB1 and DEFA loci. The cumulative burden of risk alleles is strongly associated with age at disease onset. Most loci are either directly associated with risk of inflammatory bowel disease (IBD) or maintenance of the intestinal epithelial barrier and response to mucosal pathogens. The geospatial distribution of risk alleles is highly suggestive of multi-locus adaptation, and genetic risk correlates strongly with variation in local pathogens, particularly helminth diversity, suggesting a possible role for host–intestinal pathogen interactions in shaping the genetic landscape of IgAN.